GlassScriptPhysician profile
David Edward Wrobleski
NPI 1831155118
$6,552.37
in general payments reported to CMS, 2019-2025
14 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $689 · 2021: $937 · 2022: $968 · 2023: $858 · 2024: $929 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,756.60 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Resonate El Icd Vr |
| Abbott Laboratories | $2,518.81 | 2019-2025 | Aveir, Ensite Precision, Quadra Assura |
| Philips North America LLC | $256.82 | 2020-2024 | (9520) Igt Devices Undivided |
| Medtronic, INC. | $237.20 | 2023 | Micra, Selectsecure |
| Elutia, INC. | $154.26 | 2021 | |
| Medtronic Vascular, INC. | $129.83 | 2019 | |
| Angiodynamics, INC. | $121.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $121.03 | 2019 | |
| Amgen INC. | $109.65 | 2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $53.58 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $30.84 | 2019 | |
| Renalytix Ai, INC. | $24.62 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Amarin Pharma, INC. | $22.89 | 2019 | |
| Biotronik INC. | $14.90 | 2025 | Amvia Edge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wrobleski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.